Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2024-01-08 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Ipsen – Half year statement – 2023 12 31
Regulatory Filings Classification · 1% confidence The document is titled "REGULATED INFORMATION" and specifically details the status of a "liquidity agreement" as of December 31, 2023, including share and cash balances, and transaction volumes (purchases and sells) executed between July 1st and December 31st, 2023. This type of disclosure, relating to market stabilization or liquidity provision activities, is a specific regulatory disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or an Interim Report (IR). It is a specific regulatory announcement concerning market operations. Since there is no specific code for 'Liquidity Agreement Update,' and it is a formal, regulated disclosure, it fits best under the general regulatory filing category, RNS, as it is a specific, non-standard disclosure. However, upon reviewing the definitions, the content strongly relates to the company's own shares being traded under a specific agreement. This is very close to 'Transaction in Own Shares' (POS), which covers share repurchase/issuance. While this is a liquidity agreement, the core activity reported is the execution of share purchases and sells by the designated agent on behalf of the company. Given the explicit reporting of purchase and sell transactions involving the company's own stock, POS is a strong candidate. However, POS is usually for direct buybacks/sales. Since this is a formal, regulated update on a specific financial arrangement (liquidity agreement), RNS (General regulatory announcements and fallback) is the safest classification if POS is interpreted strictly as direct company action rather than agent action under an agreement. Let's re-evaluate the options. It is a formal regulatory announcement (RNS). It is not a dividend (DIV), management change (MANG), or director dealing (DIRS). It is a specific financial operation update. Given the nature of reporting on transactions involving the company's own stock under a formal agreement, and lacking a specific 'Liquidity Update' code, RNS is the most appropriate general regulatory classification for this specific, non-standard financial disclosure.
2024-01-08 English
Ipsen – Bilan semestriel – 2023 12 31
Regulatory Filings Classification · 1% confidence The document is titled "Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF" (Semi-annual balance sheet of the liquidity contract between IPSEN and NATIXIS ODDO BHF) and reports on the status and transactions executed under a liquidity contract (share buyback/stabilization agreement) for the period July 1, 2023, to December 31, 2023. This activity—the company managing its own shares through a third party—is specifically defined as 'Transaction in Own Shares' (POS). It is not a general financing update (CAP), an earnings release (ER), or a quarterly report (IR), but a specific report on share repurchase/stabilization activities.
2024-01-08 French
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of December 31, 2023. This structure is characteristic of a mandatory periodic disclosure regarding the capital structure and voting rights, which often falls under general regulatory announcements or specific capital change reporting. Given the options, this is a specific regulatory filing concerning the share capital structure, but it is not a standard 10-K, IR, or ER. It is a notification about the composition of the share capital and voting rights. While 'SHA' (Share Issue/Capital Change) is related, this specific monthly disclosure format, especially when mandated by regulators, often defaults to a general regulatory filing category if a more precise one isn't available. However, since it directly reports on the total number of shares and voting rights, it is most closely aligned with capital structure updates. Given the French context and the nature of the disclosure (monthly update on total shares/votes), it fits best under a general regulatory filing (RNS) or potentially a capital change notification (SHA). Since it's a routine monthly update on the *total* structure rather than a specific transaction (like a buyback or new issue), RNS is a safer general regulatory classification, but SHA covers capital structure changes. Let's re-evaluate the definitions. SHA is for 'new share issues, stock splits, or other capital changes.' This is a report *on* the current capital structure. RNS is the general regulatory fallback. Given the highly specific nature of the data (total shares/votes), and the lack of a specific 'Voting Rights Disclosure' code, RNS (Regulatory Filings) is the most appropriate general category for this mandatory regulatory update that doesn't fit the other specific financial report types.
2024-01-05 French
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Monthly information relative to the total number of voting rights and shares composing the share capital' and explicitly references French regulatory articles (AMF). It provides a table detailing the total number of shares and voting rights as of a specific date (December 31, 2023). This content directly relates to tracking ownership structure and voting power, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category, as it is a formal monthly disclosure of voting rights status, even though it is not the final result of a specific vote. It is a recurring regulatory disclosure about voting rights.
2024-01-05 English
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information relative to the total number of voting rights and shares composing the share capital" and references French regulatory bodies (AMF). It provides a table detailing the total number of shares and voting rights as of a specific date (November 31, 2023). This type of periodic disclosure regarding the composition of share capital and voting rights is a specific regulatory requirement, often related to major shareholdings or capital structure transparency. It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). It most closely aligns with a specific regulatory disclosure concerning share capital structure, which fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Monthly Voting Rights Disclosure'. However, given the content focuses purely on the number of shares and voting rights, it is a very specific type of regulatory filing. Since 'Major Shareholding Notification' (MRQ) deals with *changes* in ownership thresholds, and this document reports the *total* structure, RNS is the most appropriate fallback for a specific, non-standard regulatory report. Given the context of share capital reporting, RNS is the best fit among the provided options for a mandatory, periodic regulatory disclosure that isn't a primary financial statement or management report.
2023-12-07 English
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of November 30, 2023. This content directly relates to reporting changes in the capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA), as it reports the current state of shares and voting rights, often a required periodic disclosure related to capital structure.
2023-12-07 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.